UNIMPAIRED AUTOREACTIVE T-CELL TRAFFIC WITHIN THE CENTRAL-NERVOUS-SYSTEM DURING TUMOR-NECROSIS-FACTOR RECEPTOR-MEDIATED INHIBITION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
H. Korner et al., UNIMPAIRED AUTOREACTIVE T-CELL TRAFFIC WITHIN THE CENTRAL-NERVOUS-SYSTEM DURING TUMOR-NECROSIS-FACTOR RECEPTOR-MEDIATED INHIBITION OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, Proceedings of the National Academy of Sciences of the United Statesof America, 92(24), 1995, pp. 11066-11070
The critical role of tumor necrosis factor (TNF) as a mediator in auto
immune inflammatory processes is evident from in vivo studies with TNF
-blocking agents, However, the mechanisms by which TNF, and possibly a
lso its homologue lymphotoxin alpha, contributes to development of pat
hology in rheumatoid arthritis and Crohn disease and in animal models
like experimental autoimmune encephalomyelitis is unclear, Possibiliti
es include regulation of vascular adhesion molecules enabling leukocyt
e movement into tissues or direct cytokine-mediated effector functions
such as mediation of tissue damage, Here we shelf that administration
of a TNF receptor (55 kDa)-IgG fusion protein prevented clinical sign
s of actively induced experimental autoimmune encephalomyelitis. Signi
ficantly, the total number of CD4(+=)T lymphocytes isolated from the c
entral nervous system of clinically healthy treated versus diseased co
ntrol animals was comparable, By using a CD45 congenic model of passiv
ely transferred experimental autoimmune encephalomyelitis to enable tr
acking of myelin basic protein-specific effector T lymphocytes, preven
tion of clinical signs of disease was again demonstrated in treated an
imals but without quantitative or qualitative impediment to the moveme
nt of autoreactive T lymphocytes to and within the central nervous sys
tem, Thus, despite the uninterrupted movement of specific T lymphocyte
s into the target tissue, subsequent disease development was blocked,
This provides compelling evidence for a direct effector role of TNF/ly
mphotoxin alpha in autoimmune tissue damage.